Forte Biosciences
FBRX
33 hedge funds and large institutions have $127M invested in Forte Biosciences in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 4 reducing their positions, and 4 closing their positions.
275% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 4
223% more capital invested
Capital invested by funds: $39.3M → $127M (+$87.7M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
70.22% more ownership
Funds ownership: 78.79% → 149.01% (+70%)
14% more funds holding
Funds holding: 29 → 33 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$9.23M |
| 2 |
FAM
Fred Alger Management
New York
|
+$6.09M |
| 3 |
O
OrbiMed
New York
|
+$5.2M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.26M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$4.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.14M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$547K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$263K |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$143K |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$51.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $1.95K | – | – | – |
|
27
Group One Trading
Chicago,
Illinois
| $1.34K | – | – | – |
|
28
Bank of America
Charlotte,
North Carolina
| $711 | +$77 | +9 | +20% |
|
|
SS
29
SBI Securities
Tokyo,
Japan
| $155 | – | – | – |
|
30
BNP Paribas Financial Markets
Paris,
France
| $103 | – | – | – |
|
|
RFG
31
REAP Financial Group
Austin,
Texas
| $39 | – | – | – |
|
32
Wells Fargo
San Francisco,
California
| $26 | +$17 | +2 | New |
|
33
UBS Group
Zurich,
Switzerland
| $13 | -$4.53K | -526 | -100% |
|
|
FCM
34
Farallon Capital Management
San Francisco,
California
| – | -$547K | -70,429 | Closed |
|
|
ACP
35
Acuta Capital Partners
Redwood City,
California
| – | -$143K | -18,469 | Closed |
|
|
TRCT
36
Tower Research Capital (TRC)
New York
| – | -$13.9K | -1,792 | Closed |
|
37
JP Morgan Chase
New York
| – | -$23 | -3 | Closed |
|
FBRX Hedge Fund Activity: Q2 2025 in Review
33 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q2 2025, worth a combined $127M — up 223% from $39.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new FBRX positions and 4 closed out — a net gain of 4 holders — while 15 added to existing stakes and 4 trimmed.
The largest buyer was Federated Hermes, opening a new position worth an estimated $9.23M. The largest seller was Ikarian Capital, cutting an estimated $1.14M.
- 33 institutional investors held Forte Biosciences (FBRX) as of Q2 2025, up from 29 in Q1 2025.
- Funds reported $127M of Forte Biosciences stock for Q2 2025, up 223% quarter-over-quarter.
- 8 funds opened new Forte Biosciences positions in Q2 2025 and 4 closed out, a net change of +4 holders.
- The largest Forte Biosciences buyer in Q2 2025 was Federated Hermes, an estimated $9.23M added.
- The largest Forte Biosciences seller in Q2 2025 was Ikarian Capital, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2025.